logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10323022 B1

PDFFull Text
Date of Patent:
Jun. 18, 2019

Filed:

Dec. 12, 2017

Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors

Applicant:

Array Biopharma Inc., Boulder, CO (US);

Inventors:

Shelley Allen, Boulder, CO (US);

Steven W. Andrews, Boulder, CO (US);

James F. Blake, Boulder, CO (US);

Kevin R. Condroski, San Diego, CA (US);

Julia Haas, Boulder, CO (US);

Lily Huang, Austin, TX (US);

Yutong Jiang, Boulder, CO (US);

Timothy Kercher, Boulder, CO (US);

Gabrielle R. Kolakowski, Boulder, CO (US);

Jeongbeob Seo, Baltimore, MD (US);

Assignee:

Array BioPharma Inc., Boulder, CO (US);

Attorneys:

Viksnins Harris Padys Malen LLP

Sarah S. Mastous

Primary Examiner:

Rita J Desai

Int. Cl.
CPC ...
C07D 403/12 (2006.01); A61K 31/4162 (2006.01); A61K 31/4155 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 491/04 (2006.01); C07D 495/04 (2006.01); A61K 31/4178 (2006.01); A61K 31/4192 (2006.01); A61K 31/4196 (2006.01); A61K 31/422 (2006.01); A61K 31/4245 (2006.01); A61K 31/427 (2006.01); A61K 31/4375 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); C07D 491/048 (2006.01);
U.S. Cl.
CPC ...
C07D 403/12 (2013.01); A61K 31/4155 (2013.01); A61K 31/4162 (2013.01); A61K 31/4178 (2013.01); A61K 31/4192 (2013.01); A61K 31/4196 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 31/4245 (2013.01); A61K 31/4375 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 491/04 (2013.01); C07D 491/048 (2013.01); C07D 495/04 (2013.01); Y02A 50/414 (2018.01);
Abstract

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R, R, R, R, R, R, X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Find Patent Forward Citations

Loading…